Abstract
Over the last decade advanced therapies for the management of pulmonary arterial hypertension have been introduced. These agents have also been effective in reducing pulmonary vascular resistance in patients with Eisenmenger syndrome. Specific guidelines focusing on modern therapies for Eisenmenger syndrome however do not exist to date. More recently, clinical trials in patients with Eisenmenger syndrome demonstrated a significant clinical improvement with favorable safety and tolerability profile. This review aims to summarize newly reported pharmacological agents used in patients with Eisenmenger syndrome.
Keywords: Congenital heart disease, endothelin receptor antagonists, eisenmenger syndrome, phosphodiesterase type-5 inhibitors, prostanoids, pulmonary arterial hypertension.
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:Eisenmenger Syndrome: Recent Advances in Pharmacotherapy
Volume: 11 Issue: 4
Author(s): Sarmad Said, Mateo Porres-Aguilar, Mateo Porres-Munoz and Debabrata Mukherjee
Affiliation:
Keywords: Congenital heart disease, endothelin receptor antagonists, eisenmenger syndrome, phosphodiesterase type-5 inhibitors, prostanoids, pulmonary arterial hypertension.
Abstract: Over the last decade advanced therapies for the management of pulmonary arterial hypertension have been introduced. These agents have also been effective in reducing pulmonary vascular resistance in patients with Eisenmenger syndrome. Specific guidelines focusing on modern therapies for Eisenmenger syndrome however do not exist to date. More recently, clinical trials in patients with Eisenmenger syndrome demonstrated a significant clinical improvement with favorable safety and tolerability profile. This review aims to summarize newly reported pharmacological agents used in patients with Eisenmenger syndrome.
Export Options
About this article
Cite this article as:
Said Sarmad, Porres-Aguilar Mateo, Porres-Munoz Mateo and Mukherjee Debabrata, Eisenmenger Syndrome: Recent Advances in Pharmacotherapy, Cardiovascular & Hematological Agents in Medicinal Chemistry 2013; 11 (4) . https://dx.doi.org/10.2174/1871525712666140321095519
DOI https://dx.doi.org/10.2174/1871525712666140321095519 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Transforming Growth Factor-β, Cell Signaling and Cardiovascular Disorders
Current Vascular Pharmacology Diagnoses of Gastrointestinal Cancers After Gastrointestinal Bleeding in Patients Receiving Clopidogrel or Warfarin
Current Drug Safety Curcumin Activates Erythrocyte Membrane Acetylcholinesterase
Letters in Drug Design & Discovery Sesamol Induces Apoptosis by Altering Expression of Bcl-2 and Bax Proteins and Modifies Skin Tumor Development in Balb/c Mice
Anti-Cancer Agents in Medicinal Chemistry Recent Progress in Pharmacological Research of Antioxidants in Pathological Conditions: Cardiovascular Health
Recent Patents on Anti-Infective Drug Discovery Vitamin D3, D2 and Arterial Wall Properties in Coronary Artery Disease
Current Pharmaceutical Design Mechanisms Underlying Beneficial Health Effects of Tea Catechins to Improve Insulin Resistance and Endothelial Dysfunction
Endocrine, Metabolic & Immune Disorders - Drug Targets Potential Role of TRAIL in the Management of Autoimmune Diabetes Mellitus
Current Pharmaceutical Design Pharmacology of Adenosine A2A Receptors and Therapeutic Applications
Current Topics in Medicinal Chemistry Nanocarriers Mediated Topical Drug Delivery for Psoriasis Treatment
Current Drug Metabolism Selective Serotonin Re-Uptake Inhibitors for the Treatment of Depression in Coronary Artery Disease and Chronic Heart Failure: Evidence for Pleiotropic Effects
Cardiovascular & Hematological Agents in Medicinal Chemistry Effects of Intensive Blood Pressure Control in Patients with Evident Cardiovascular Disease: An Investigation Using the SPRINT Study Data
Current Vascular Pharmacology Pleiotropic Effects of Nifedipine on Atherosclerosis
Current Pharmaceutical Design Bioactive Small Molecules: Promising Novel Therapies in Cardiovascular Diseases – PART II
Current Topics in Medicinal Chemistry Trastuzumab-Induced Cardiotoxicity: Is it a Personalized Risk?
Current Drug Targets Leptin-Induced Endothelial Dysfunction: A Target for Therapeutic Interventions
Current Pharmaceutical Design Stable Angina Pectoris: Current Medical Treatment
Current Pharmaceutical Design Chronopharmaceuticals: Hype or Future of Pharmaceutics
Current Pharmaceutical Design Vitamin D and Cardio-Metabolic Risk Factors in Overweight Adults: An Overview of the Evidence
Current Pharmaceutical Design Visit-to-visit Blood Pressure Variability and Arterial Stiffness: Which Came First: The Chicken or the Egg?
Current Pharmaceutical Design